Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
– Data Show that HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Reduced Relapse Rate Versus Placebo in CIDP Patients When Used as a Maintenance Therapy – Company Continues to Analyze Data with Goal of Submitting Regulatory Applications in the US and EU in FY2022 OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today … [Read more…]
